All filters
Slidesets
Pharmacological perspective- José Moltó, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Toxicity and co-morbidities perspective- José Ignacio Bernardino, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Virological perspective- Santiago Moreno, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Clinical case on reduced drug regimen with integrase inhibitors- Federico Pulido, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
HIV Prevention 2.0- Charles Boucher, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Eficacia y seguridad de dolutegravir más rilpivirina en la vida real. Resultados a 24 semanas. Estudio DORIVIR- J. Santos
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Dolutegravir and lamivudine as dual maintenance therapy- R. Montejano
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Reasons for discontinuation of dual therapy with dolutegravir and riplivirine- R. Montejano
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Dolutegravir (DTG) based antiretroviral therapy (ART) discontinuation in clinical practice- V. Moreno-Torres
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Experiencia con Inhibidores de la Integrasa en un hospital terciario- I. Mur
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
(Abstract) Case Control study of the oral microbiome in HIV uninfected individuals compared to HIV positive individuals before and after HAART | D. Malamud
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
The “Window of Opportunity”: Harnessing the Pediatric Immune Landscape for Life-Long Vaccine- Elicited Protection | Sallie Permar, MD, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
(Abstract) Enteric virome analysis of non-invasive samples from gorillas by next-generation sequencing and association with SIV infection | M. D’arc
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
Functional Role of Gut Microbiota in Chronic Liver Disease | Gary Wu, MD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
The Mycobiome and How it Influences Disease | Mahmoud Ghannoum, PhD, MBA
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
Live Biotherapeutics: How the Vaginal Microbiome Can be Modified to Prevent HIV Infection | Laurel Lagenaur, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
The NIH’s human microbiome project | Lita Proctor, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
The Human Microbiome and Cancer: New Opportunities For Population Studies | Emily Vogtmann, PhD, MPH
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
Oral microbiota in relation to HIV infection and oral infection in perinatally HIV-infected adolescents | Bruce Paster, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Meeting
European HIV Clinical Forum 2016
Slidesets
Impact on: Adherence/tolerability - Ian McGowan, MB, ChB, DPhil, MD, FRCP
Presented at:
European HIV Clinical Forum 2016
Slidesets
Impact on: Virology/Resistance - Daniel Kuritzkes, MD
Presented at:
European HIV Clinical Forum 2016